Clinical Trials
11 trialsNCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT02607202 2024-01-26
AGNOSTOS
Fondazione del Piemonte per l'Oncologia
Phase 2 Completed
NCT00357630 2020-11-02
Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00066781 2017-04-04
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02590055 2015-10-28
Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary
Samsung Medical Center
Phase 2 Unknown
NCT00119314 2015-05-27
Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT00458315 2015-05-08
Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor
Rigshospitalet, Denmark
Phase 2 Withdrawn
NCT00014456 2013-08-28
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT00193596 2013-05-03
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 3 Completed
NCT00353145 2012-08-02
Gemox as First and Second Line Therapy in Unknown Primary Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00148135 2008-01-10
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site
University of Michigan Rogel Cancer Center
Phase 2 Terminated